Compare BIO-TECHNE Corp (TECH) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs United Microelectronics Corp — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while United Microelectronics Corp trades at $22.47 (market cap $54.48B). The key difference: United Microelectronics Corp is far larger — about 4.8× BIO-TECHNE Corp's market cap, and United Microelectronics Corp pays the higher dividend (1.84%). Which is the better fit depends on your goals.
| TECH | UMC | |
|---|---|---|
Market Cap | $11.34B | $54.48B |
Sector | Health | Technology |
52-Week High | $72.48 | $28.02 |
52-Week Low | $43.31 | $6.76 |
Enterprise Value | $11.36B | $51.52B |
Dividend Yield | 0.44% | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
UMC trades at $21.82, up 5.06% in 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.54 versus $0.16 expected, and announced a $0.41 dividend payable in August 2026. Revenue trends show recovery, with 2026 projections at $250.7B and net income margin improving to 32.75%.
Outlook is positive due to earnings momentum and AI expansion plans, but risks include competitive pressures and volatility from AI spending concerns. Analyst consensus is mixed with 27% buy ratings, suggesting cautious optimism amid high valuation multiples like P/E of 20.96.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
